Study of TJ210001 Administered in Subjects With Relapsed or Refractory Advanced Solid Tumors

NCT04678921 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

16

Enrollment

INDUSTRY

Sponsor class

Conditions

Solid Tumor
Metastatic Cancer
Advanced Cancer

Interventions

DRUG: TJ210001

Sponsor

I-Mab Biopharma US Limited